Key Considerations for Watchman Device Adoption

With the prevalence of atrial fibrillation (AF) on the rise, novel devices and medical therapies have entered the market to help providers manage this challenging patient population. One such device is the Watchman, an interventional therapy that aims to mitigate stroke risk in AF patients.

While the Watchman has generated considerable enthusiasm among some CV program leaders, it has also been the subject of significant scrutiny regarding its clinical effectiveness.

Log in to access this.

Full access to this content is reserved for Service Line Strategy Advisor members.
Log in or learn how membership works.

Next, Check Out

Report from the Field: Lessons from Watchman Device Early Adopters